(Total Views: 264)
Posted On: 12/29/2017 3:23:07 PM
Post# of 15624
Re: truebeliever #11712
GWPH has a market cap of $3.36 billion. With the currently outstanding shares, our share price would be about $25 at about that market cap. In our case, I don't believe it will require having drugs approaching approval for sale, as is the case with GWPH, rather we will achieve it for product sales and simultaneously may have the same products in clinical trials.
I wish I could say how quickly this could occur, but I believe the company will consider releasing the product for sales by a variety of agents once the products have demonstrated safety, but this is my belief, not something the company committed to.
If I'm correct, I think it's possible that our cream may be available in the second quarter of 2018, and possibly the sublingual tablet by late in the year. Sales wouldn't initially give us a $3 billion market cap, but once effectiveness is clearly established anecdotally, it may not take that long to achieve. Depending on when product actually reaches the market, I wouldn't be surprised to see $20 or more within 12 months of the initiation of product sales.
Gary
I wish I could say how quickly this could occur, but I believe the company will consider releasing the product for sales by a variety of agents once the products have demonstrated safety, but this is my belief, not something the company committed to.
If I'm correct, I think it's possible that our cream may be available in the second quarter of 2018, and possibly the sublingual tablet by late in the year. Sales wouldn't initially give us a $3 billion market cap, but once effectiveness is clearly established anecdotally, it may not take that long to achieve. Depending on when product actually reaches the market, I wouldn't be surprised to see $20 or more within 12 months of the initiation of product sales.
Gary
(0)
(0)Scroll down for more posts ▼
